The predictive performance of the ANCA renal risk score in patients over 65 years of age with renal ANCA-associated vasculitis

Quentin de Berny,Momar Diouf,Rafik Mesbah,Thomas Quemeneur,Céline Lebas,Dominique Guerrot,Eric Hachulla,Jean-Baptiste Gibier,Carole Cordonnier,Arnaud Francois,Victor Gueutin,Gabriel Choukroun,Dimitri Titeca-Beauport

DOI: https://doi.org/10.1093/ckj/sfae135

2024-04-29

Clinical Kidney Journal

Abstract:Abstract Background The anti-neutrophil cytoplasmic antibody (ANCA) renal risk score (ARRS) for predicting renal survival in ANCA-associated vasculitis (AAV) had not previously been validated in adults over 65 years of age and presenting impairments associated with an aging kidney, a high cardiovascular comorbidity burden, and prevalent microscopic polyangiitis. Methods We retrospectively studied a cohort of 192 patients over 65 years of age (median [interquartile range] age: 73 [68; 78]), including 17.2% with renal-limited vasculitis, 49.5% with microscopic polyangiitis and 33.3% with granulomatosis with polyangiitis, at six centres of northern France. The primary study endpoint was the cumulative incidence of end-stage kidney disease (ESKD, maintenance of dialysis for at least 3 months) at 12 months, with death considered as a competing event. Results The median serum creatinine concentration at diagnosis was 300 [202; 502] μmol/L, and 48 (25.0%) patients required dialysis at presentation. The ARRS was high in 43 (22.4%) patients, medium in 106 (55.2%), and low in 43 (22.4%). The cumulative incidence of ESKD at 12 months was 0% in the low-risk group, 13.0% [7.6–20.0] in the medium-risk group, and 44.0% [29.0–58.0] in the high-risk group (p < 0.001). In the subgroup of 149 patients presenting a medium or high score, the ARRS had a C-index of 0.66 [0.58–0.74] for the prediction of ESKD at 12 months; this rose to 0.86 [0.80–0.90] when dialysis status at diagnosis was included. Conclusion The ARRS was a poor predictor of kidney survival at 12 months among patients over 65 years of age with renal AAV involvement—especially in the high ARRS group. The addition of dialysis status at diagnosis as an additional clinical parameter might improve the ARRS's predictive performance.

urology & nephrology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to evaluate the predictive performance of the Anti-Neutrophil Cytoplasmic Antibody (ANCA) Renal Risk Score (ARRS) in patients aged 65 and older with ANCA-associated vasculitis (AAV). Specifically, the researchers aim to verify whether ARRS can effectively predict the incidence of end-stage kidney disease (ESKD) within 12 months in these elderly patients.

### Background

1. **Insufficient Existing ARRS Validation**: Previous ARRS validation studies have primarily focused on patient groups under 65 years old, while the elderly population over 65 has a higher burden of cardiovascular comorbidities and a higher risk of chronic kidney disease.
2. **Characteristics of the Elderly Population**: The elderly population is more prone to microscopic polyangiitis (MPA), which is usually associated with poorer renal prognosis. Additionally, the kidneys of elderly individuals naturally lose glomeruli with age, leading to a decline in renal functional reserve.
3. **Challenges in Renal Function Assessment**: Distinguishing between age-related changes in renal function and disease-related changes in renal function is very difficult in the elderly population, which may affect the accuracy of ARRS.

### Research Objectives

1. **Evaluate the Predictive Performance of ARRS**: Assess the ability of ARRS to predict ESKD within 12 months in AAV patients aged 65 and older.
2. **Improve the Predictive Performance of ARRS**: Attempt to enhance the predictive accuracy of ARRS by incorporating clinical parameters such as the need for dialysis at the time of diagnosis.

### Methods

1. **Study Design**: A multicenter, observational, retrospective study that included 192 AAV patients aged 65 and older from six hospitals in northern France.
2. **Data Collection**: Collection of clinical, laboratory, and pathological data from patients, including age, gender, weight, height, BMI, medical history, ANCA types, serum creatinine levels, urine protein-creatinine ratio (uPCR), treatment regimens, etc.
3. **Endpoints**: The primary endpoint is the incidence of ESKD within 12 months, with death considered a competing event.

### Results

1. **ARRS Classification**: Low-risk group (22.4%), medium-risk group (55.2%), high-risk group (22.4%).
2. **ESKD Incidence**: Low-risk group 0%, medium-risk group 13.0% [7.6-20.0], high-risk group 44.0% [29.0-58.0] (p<0.001).
3. **Predictive Performance**: The C-index of ARRS in the overall population was 0.75 [0.68-0.81], and 0.66 [0.58-0.74] in the medium and high-risk groups. After adding the variable of the need for dialysis at the time of diagnosis, the C-index significantly increased to 0.86 [0.80-0.90].

### Conclusion

1. **Limited Predictive Ability of ARRS**: ARRS has poor predictive ability for ESKD within 12 months in AAV patients aged 65 and older, especially in the high-risk group.
2. **Importance of Dialysis Status**: Incorporating the variable of the need for dialysis at the time of diagnosis can significantly improve the predictive performance of ARRS, aiding in clinical decision-making.

### Potential Impact

1. **Clinical Decision-Making**: The predictive ability of ARRS in the elderly population is limited, but combining it with the dialysis status at diagnosis can better guide treatment choices.
2. **Future Research Directions**: Further research is needed to optimize ARRS to make it more suitable for the elderly population.